ABSTRACT 26 27
Background 28
Non-muscle-invasive bladder cancer (NMIBC) causes a considerable health burden due to 29 the high recurrence and progression rates. Past studies have identified multiple candidate loci 30 associated with NMIBC prognosis, albeit lacking validation. Moreover, scarce reports exist 31 on genetic susceptibility to independent prognostic predictors of NMIBC, such as stage or 32
grade. 33
Objective 34
To investigate genetic associations with NMIBC tumour and patient characteristics at the 35 time of diagnosis. 36
Design, Setting, and Participants 37
A sample of 653 NMIBC cases come from the Bladder Cancer Prognosis Programme 38 (BCPP). Replication of the significant findings was conducted in the Nijmegen Bladder 39
Cancer Study (NBCS) cohort (N=1470). 40
Outcome Measurements and Statistical Analysis 41
Genome-wide association study (GWAS) was carried out for outcomes of tumour size (as 42 continuous variable in centimetres), stage (Tis and T1 vs Ta), grade (G3 vs G2 and G1), and 43
age (as continuous (years) and dichotomous (70.2 years as a cut-off) variables). 44

Results and Limitations 45
Significant (P<5E-08) associations (N=61) with tumour size, stage, grade, and age were 46 identified in the GWAS discovery stage. None of the variants were independently 47 significantly associated in the replication cohort. A meta-analysis of both cohorts suggests 48 rs180940944 (13q13.3 locus, NBEA) was associated with tumour size as a continuous 49 variable (ß=0.9 cm, p=2.92E-09). However, other SNPs in this region did not show evidence 50 of association in the meta-analysis. 51
Conclusions 52
Our study suggests rs180940944 (NBEA) is associated with an increased NMIBC tumour size 53 at the time of diagnosis. Given study limitations, further replication is essential to validate the 54 finding. 55
Patient Summary 56
Current study reports on a genome-wide association study on non-muscle-invasive bladder 57 cancer tumour and patient characteristics. We suggest NBEA gene might be associated with 58 increased tumour size at the time of diagnosis. The result must be replicated to establish 59 Urinary bladder cancer (UBC) accounts for 430 000 new cases worldwide annually, with 70-76 80% of new cases presenting as non-muscle-invasive bladder cancer (NMIBC) [1] . NMIBC 77 causes significant burden on healthcare systems due to high recurrence and progression rates 78
(5-year recurrence rate: 50-70%, 5-year progression rate: 10-30%) [1] . Considerable clinical 79 improvements could be made by better, even personalised, prognostication and risk 80 stratification [1] . There have been several attempts to apply different approaches for accurate 81 disease prognostication, and although descriptive on a population-level, a substantial lack of 82 precision of individual outcomes remains [2], requiring ongoing improvement. 83
Few candidate-gene studies of UBC prognosis exist, with limited successful replication [3] [4] [5] . 84
A recent study reported that out of 114 reported loci for UBC progression and prognosis, 85 only six single nucleotide polymorphisms (SNPs) showed significant associations in an 86 independent cohort, namely: NMIBC progression (rs6678136 (RGS4), rs11585883 (RGS5)), 87 recurrence among Bacillus Calmette-Guérin (BCG)-treated NMIBC patients (rs1799793 88 (ERCC2), rs187238 (IL18)), and muscle-invasive bladder cancer (MIBC) overall survival 89 (rs12035879 (RGS5), rs2075786 (TERT)) [3] . Powerful GWAS studies on NMIBC 90 prognosis show promise, but are still ongoing [6] . 91
A previous attempt to include genetic variation failed to increase prognostic tool performance 92 [7] , suggesting the issue is more complex. However, latter study utilised a relatively small 93 panel of SNPs (170,000), which has lower power of discovering significant loci in 94 comparison to genotype-imputed sets harbouring millions of variants for analysis [8] . The 95 inter-study lack of consensus might be due to several reasons: spurious findings, lack of 96 statistical power, and variation in outcome definition. 97
Other studies also suggest significant genetic signals might be only present for tumours of 98 certain grade or stage [9, 10] 
MATERIAL AND METHODS 125
Participants and genotyping 126
BCPP is a prospective cohort that initially recruited 1,544 eligible patients and is described in 127 more detail elsewhere [11] . Clinical data on stage, grade, and size of tumours and 128 demographic information (age, gender) were gathered with bespoke case report forms. 129
Tumour size of the largest tumour was established visually while performing cystoscopy. 130
Blood samples of 888 participants with confirmed UBC were genotyped on the Illumina 131 Infinium OmniExpress-24 BeadChip array at deCODE Genetics (Iceland). 132
Tumours of stages pTa, pT1, or pTis were included to limit our analyses to NMIBC, resulting 133 in a dataset of 712 cases. 134
Quality control (QC) 135
QC procedures were carried out using PLINK v1.90 [12] . The exact thresholds applied and 136 number of exclusions per step are outlined in Figure 1 . All analyses were adjusted for participant gender and first five genetic principal components 167 to increase estimate precision and to adjust for any potential residual population stratification 168
bias. An association was held significant if p-value <5E-08, and promising if below 5E-06. 169
Post-GWAS power calculations were carried out in web-based GAS Power Calculator [18] . 170
Manhattan and QQ graphs were plotted for each tested outcome. For significant hits, regional 171 association plots were constructed using LocusZOOM tool [19] , except for hits that have not 172 yet been assigned an ID (rsID). 173
Functional annotation 174
Identified significant SNPs were mapped using a web-based SNPnexus tool [20] (Figure 1) 
RESULTS
200
Baseline clinical characteristics of the discovery and replication cohorts are shown in Table  201 1. 202
Majority of cases in BCPP were male (78.1%), with an average age of 70 years. Tumour size 203 mean was 2.5 cm, and most of the participants were diagnosed with stage Ta (68%) and T1 204 (30.5%) tumours. More than a third of cases presented as G2 (37.5%), followed by G3 205 (31.7%) and G1 (29.2%) NMIBC. The distribution of variable categories and measures were 206 similar between the BCPP and NBCS cohorts. 207
In the discovery-stage analysis, a total of 61 SNPs, corresponding to 29 different regions, 208
showed genome-wide statistically significant associations with at least one of the outcomes. 209
Out of those, 20 loci were mapped to genes (all intronic regions) ( Table 2 ). Significant 210 associations were observed for size and age as continuous variables, as well as for binary 211 outcomes of stage, grade, and age. 212
Most of the SNPs (N=47) were found to be associated with tumour size, the effect sizes 213 ranging from 0.65 (rs35225990 in FAM194B, p= 2.85E-08) to 2.6 (rs370572716 in 9p13.1, 214 p=4.04E-09) centimetres ( Table 2) . 215
One SNP in 9q22.32, rs142492877, showed statistically significant association with 216 decreased age at diagnosis of almost one year (ß=-0.95, SE=0.16, p=1.05E-08). Age as a 217 binary trait showed associations in the same direction, although in a different genomic region 218 (7q31.33) with an odds ratio (OR) ranging between 2.46 (rs17149580, p=2.18E-08) and 2.51 219 (rs17149636, p=1.62E-08) across eight SNPs. 220
The 14q11.2 locus showed strong associations with being diagnosed with a higher grade of 221 NMIBC (rs15091489 in the TRAV16 gene (OR=3.42, 95%CI: 2.11-5.55, p=5.13E-09) and 222 rs116923391 (OR=3.86, 95% CI: 2.38-6.26, p=2.07E-10)). plots for all other tested outcomes are available in the Supplementary Figures 1-6) . 231
Regional association plot of 13q13.3 (Figure 3 ) in the BCPP confirms high LD with 232 surrounding variants, all mapping to the NBEA gene (although they did not reach the 233 statistical significance). Regional association plots for the remaining SNPs identified in the 234 discovery stage are presented in Supplementary Figures 7-33 . 235
In the replication stage, 50 out of 61 SNPs were available to test in NBCS ( Table 2) and function [24] . NBEA dysregulation does not affect the establishment of synapses per se, 258 but rather their intra-cellular organisation [24] . An in-depth analysis revealed impaired 259 synaptic ability was mostly due to the inappropriate distribution of actin, a protein essential 260 for synapse cytoskeleton structure [24] . The effect is most likely present due to alterations in 261 the Golgi-dependent processes of inter-and intra-cellular compound trafficking, including 262 actin and neural receptors [24] . 263
The synaptic alterations are likely to be the contributing cause of autism spectrum disorders 264
[24]; however, the Golgi-related pathway may have a wider phenotypic manifestation [25] , 265 including cancer. The prognostic utility of NBEA has been investigated in gastric cancer [26] 266 and oropharyngeal squamous cell carcinomas (OPSCC) [27] , with promising results. 267
Collectively, these observations implicate the pleiotropic nature of NBEA effect across a 268 variety of traits. 269
In our study, we suggest there is an association between NBEA and increased NMIBC tumour 270 size. The role of Golgi complex in cancer progression has been reported independently, and 271 disruptions in normal protein transportation can contribute to increased tumour size and, 272 eventually, progression [25] . 273
Our findings should be interpreted cautiously. Substantial sample sizes of specific 274 phenotypes such as ours are rare, and suffer from limited power to capture true genetic 275 associations, and spurious associations due to random effects cannot be ruled out. Our post-276 hoc power calculations [18] , underscore the importance of current analysis being ran on 277 bigger cohorts (e.g. association rs150914897 (14q11.2) of an OR=3.42 had power of 79%, 278 but it drops to only 16% for an OR=2.5, hence we may have missed existing associations of 279 more modest effect size). 280
Furthermore, tumour size measurements are subject to variability, degree of which is difficult 281 to establish. The lack of any genome-wide significant associations for categorised tumour 282 size (</≥ 3 cm [17]) adds substantial caution in consideration of our main findings and study 283 power. However, clinically-relevant tumour size categories may not be adequate in a genetic 284 context, and different categorisation may be used in future analyses. 285
Our study only focused on NMIBC instead of a merged group of UBC, and we are unable to 286 comment on whether these genetic loci are relevant for advanced UBC. Given considered 287 limitations, we see this study as true to the GWAS design of hypothesis-generating nature, 288 instead of one offering conclusive findings. Hence, further replication is of essence to 289 establish validity of described results. 290
The 13q13.3 locus has not been observed in prior studies on NMIBC. It might be due to us 291 using an independent prognostic marker of NMIBC (i.e. tumour size) instead of recurrence 292 and/or progression as an outcome. Larger tumour indicates a worse disease course [17] , but 293 there are other components that contribute to NMIBC prognosis. In a clinical setting, each 294 tumour characteristic (e.g. size) carries a different weighting [17] , collectively contributing to 295 an endpoint (e.g. recurrence). 296
Importantly, powerful studies on UBC risk have already shown some signals to only be 297 associated with MIBC (UBC of T2-T4) [10] . Furthermore, a genome-wide methylation 298 investigation on high-grade NMIBC cases revealed epigenetic changes different from their 299 low-grade counterparts [9] . Direct comparability of these reports is limited, but we see the 300 unravelling genetic complexity within UBC being a connecting thread between all studies. 301
We therefore believe it is likely separate genetic relationships are present for NMIBC 302 determinants, rather than overall prognostic outcomes. 
